IntelliCell enters sponsored research agreement with ICERM

IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida.  A portion of the collaborative work will be to explore the physiological characteristics of the adult autologous vascular cells that are also referred to as stromal vascular fraction cells which form the basis of the IntelliCell product.  The company also intends to explore combination therapies with patent pending bio-engineered products under development.  The Company believes that the IntelliCell product is an efficient cellular delivery platform for a variety of therapeutic applications and will look to partner with technology developers.

Said Jon Dobson, Ph.D., Professor of biomedical engineering and biomaterials at the University of Florida, "We are pleased to be working with IntelliCell. Their technology is innovative and appears to hold promise for future regenerative medicine applications.  The use of adult autologous (your own) stem cells to repair and regenerate tissues are of great interest to personalized medicine researchers." Professor Dobson is a leading researcher in bionanotechnology and nanomedicine applications and apart from regenerative medicine, his work also spans across fields as diverse as gene therapy, stem cell therapy and tumor targeting. He is also the Director of the newly formed Institute for Cell Engineering and Regenerative Medicine at the University of Florida.

Dr. Steven Victor, CEO of IntelliCell, added "This is a very exciting time for regenerative medicine companies.  We are looking forward to long and productive research collaboration with the University of Florida and Professor Dobson.  IntelliCell believes that important contributions for better medicine will result from research collaborations with our university research colleagues."   Robert Sexauer, Executive Vice President, ICBS Research, stated that "we would like to take a thought leadership position by working closely with those at the vanguard of regenerative medicine development."